In the latest session, Caredx Inc (NASDAQ: CDNA) closed at $8.20 down -3.87% from its previous closing price of $8.53. On the day, 609497 shares were traded.
Ratios:
For a deeper understanding of Caredx Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.77 and its Current Ratio is at 4.02. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
On August 15, 2023, Raymond James Upgraded its rating to Outperform which previously was Mkt Perform but kept the price unchanged to $12.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 02 ’23 when Seeto Reginald sold 2,818 shares for $6.91 per share. The transaction valued at 19,483 led to the insider holds 479,164 shares of the business.
Seeto Reginald sold 2,819 shares of CDNA for $26,762 on Sep 05 ’23. The insider now owns 481,982 shares after completing the transaction at $9.49 per share. On Aug 14 ’23, another insider, Seeto Reginald, who serves as the insider of the company, sold 576 shares for $8.89 each. As a result, the insider received 5,123 and left with 484,801 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.51 while its Price-to-Book (P/B) ratio in mrq is 1.62.
Stock Price History:
Over the past 52 weeks, CDNA has reached a high of $12.93, while it has fallen to a 52-week low of $4.80.
Shares Statistics:
A total of 51.50M shares are outstanding, with a floating share count of 49.14M. Insiders hold about 5.09% of the company’s shares, while institutions hold 99.29% stake in the company.
Earnings Estimates
There are Strategic CRISPR & Gene Editing different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $69.83, with high estimates of $301.56 and low estimates of $0.95.
Analysts are recommending an EPS of between $Technology and $Healthcare for the fiscal current year, implying an average EPS of $Consumer Cyclical.
